Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer

Alessandra Gennari, Michele De Tursi, Consiglia Carella, Enrico Ricevuto, Cinzia Orlandini, Antonio Frassoldati, Pierfranco Conte, Paolo Bruzzi, Stefano Iacobelli

Research output: Contribution to journalArticlepeer-review


Purpose This phase II study, evaluated the activity and cardiotoxicity of first-line epirubicin plus low-dose trastuzumab (LD-T) in patients with HER2 positive MBC. Methods Patients received epirubicin 90 mg/sqm every 3 weeks plus weekly LD-T (2 mg/kg loading dose, then 1 mg/kg). After 6/8 cycles of epirubicin, single agent trastuzumab was continued. Cardiotoxicity was defined as signs or symptoms of congestive heart failure (CHF), or ≥15% decline in LVEF without symptoms, or

Original languageEnglish
Pages (from-to)131-136
Number of pages6
JournalBreast Cancer Research and Treatment
Issue number1
Publication statusPublished - May 2009


  • Epirubicin
  • Low-dose trastuzumab
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer'. Together they form a unique fingerprint.

Cite this